Silence Therapeutics Plc - Amer
SLN
Last
$9.86
Day
+3.6%
1y
+84.9%
5y
-58.0%
52w
-45.8%
SPY YTD
+13.3%
XLV
+8.1%
Earnings
2026-11-0526d
EMA 21
11.09
EMA 50
11.56
EMA 200
9.33
20d high
-28.3%
5y high
-65.7%
5y range
29th
Positions held
Your positionsSLN isn't in your positions.
Add it to see shares, cost, and P&L here.
Score
-16
Hold
avoid
Signal
Strong Sell
Target
$10.58
Stop
$8.64
Stop distance
12.4%
Target vs last
+7.3%
Fundamentals
| Market cap | $591.71M | Enterprise value | $377.85M | Trailing P/E | — | Forward P/E | -25.05 |
| PEG | — | Price / book | 11.70 | Beta | 1.45 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 85.9% | Operating margin | -104.8% |
| Profit margin | 0.0% | ROE | -90.4% | ROA | -29.6% | Debt / equity | 0.00 |
| Current ratio | 7.42 | Free cash flow | -$23.57M | Analyst recommendation | buy | Mean target | $33.00 |
| 52w high | $17.58 | 52w low | $4.19 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.4M | $0.0M | $0.2M | $0.2M | — |
| Op margin | — | -3729.1% | -36650.0% | -16505.7% | -10106.7% | — |
| Net income | -$12.3M | -$15.0M | -$11.8M | -$21.0M | -$27.4M | — |
| Gross margin | — | 97.4% | 64.7% | 59.7% | 62.1% | — |
| Gross profit | $0.0M | $0.4M | $0.0M | $0.1M | $0.1M | — |
| Operating income | -$13.9M | -$15.7M | -$12.5M | -$26.2M | -$22.6M | — |
- Revenue -100% vs prior quarter ($0 vs $0.4M).
- Gross margin 97.4% (was 64.7% prior quarter).
- Operating margin expanded to -3729.1%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.6M | $43.3M | $31.6M | $21.7M | — |
| Op margin | -16056.0% | -146.4% | -203.5% | -281.9% | — |
| Net income | -$88.6M | -$45.3M | -$54.2M | -$50.3M | — |
| Gross margin | 61.5% | 72.7% | 59.3% | 37.8% | — |
| Gross profit | $0.3M | $31.4M | $18.8M | $8.2M | — |
| Operating income | -$89.8M | -$63.3M | -$64.4M | -$61.0M | — |
Headline scan
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-02 · Silence Therapeutics to Participate in Three September Investor Conferences
2026-08-12 · Silence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public Offering
2026-08-11 · Silence Therapeutics’ Divesiran Hits Phase II Goal, Sets Up Phase III PV Trial
2026-08-10 · Silence Therapeutics Announces Proposed Public Offering of $150 Million of American Depositary Shares
2026-08-10 · Silence Therapeutics Reports Second Quarter 2026 Financial and Business Results
Price (daily)
Full chart · RSI · MACD · patternsSLN · daily-22.5% over 13 sessions
Close EMA21 EMA50 EMA200
Quarterly · revenue, net income, margins
Revenue Net income Gross margin Op margin